Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-21-GWIRP-CEA: DoD Gulf War Illness, Clinical Evaluation Award

Closed Closed August 19, 2021 Opportunity W81XWH-21-GWIRP-CEA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.

• Total funding$7.2 million
• Expected awards3
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY21 GWIRP Clinical Evaluation Award supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population. The Clinical Evaluation Award targets the Verification phase of the research pipeline as outlined in Section II.A.2. Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, phase 1-2a) are encouraged under this funding opportunity. Clinical trials may be designed to evaluate pharmacologic agents (drugs or biologics), devices, clinical guidance or other approaches, and technologies supported by strong objective evidence in the GWI field. While studies of treatments repurposed from other disorders sharing GWI symptomatology will be considered (with appropriate rationale), the FY21 GWIRP encourages studies that translate qualified results from the GWI research community. Biomarker investigations must expand preliminary findings in a GWI cohort large enough to produce a statistically meaningful outcome. Biomarker study outcomes shall provide validation of use as clinical endpoints in large-scale (phase 2b-3) clinical trials. Funding from this award mechanism must support research in a Gulf War Veteran population. Proof of availability and access to necessary cohort(s) and/or critical reagents must be provided. Applications must state a realistic timeline for clinical investigation. Investigators seeking funding for a preclinical research project should consider one of the other FY21 GWIRP program announcements being offered. The requested budget must be commensurate with the phase and size of the trial proposed. Refer to Section II.D.5, Funding Restrictions for detailed funding information. Biorepository Contribution Option: In FY17, the GWIRP awarded infrastructure support for a Gulf War Illness Biorepository. The Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI has now been established for the retention and distribution of Gulf War Veteran biospecimens and/or data related to GWI research. Applicants to the FY21 GWIRP are encouraged to contribute Gulf War Veteran biospecimens and data to this repository network. The FY21 GWIRP Clinical Evaluation Award offers a Biorepository Contribution Option with higher levels of funding for qualified applications as described in Section II.D.5, Funding Restrictions.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.